AI-Enhanced Intensive Care Unit (ICU) Ventilation Weaning Market Report 2026

The artificial intelligence (AI)-enhanced intensive care unit (icu) ventilation weaning market size has grown exponentially in recent years. It will grow from $1.61 billion in 2025 to $1.99 billion in 2026 at a compound annual growth rate (CAGR) of 23.3%. The growth in the historic period can be attributed to increasing utilization of mechanical ventilation in critical care, growing icu patient volumes, rising clinical complexity in respiratory management, expansion of critical care monitoring technologies, increased adoption of data-driven icu protocols.

The artificial intelligence (AI)-enhanced intensive care unit (icu) ventilation weaning market size is expected to see exponential growth in the next few years. It will grow to $4.57 billion in 2030 at a compound annual growth rate (CAGR) of 23.1%. The growth in the forecast period can be attributed to increasing adoption of ai-driven critical care solutions, rising demand for outcome-based icu management, expansion of smart ventilator ecosystems, growing integration of predictive analytics in intensive care, increasing focus on reducing icu length of stay. Major trends in the forecast period include increasing use of predictive weaning algorithms, rising integration of real-time ventilator analytics, growing adoption of AI-assisted icu decision support, expansion of automated ventilation management, enhanced focus on reducing ventilation duration.

The rising prevalence of respiratory diseases is expected to drive the growth of the artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning market in the coming years. Respiratory diseases are medical conditions that affect the lungs and airways, disrupting normal breathing and oxygen exchange in the body. Their prevalence is increasing due to aging populations in developed countries, as older adults are more susceptible to chronic respiratory conditions because of weakened immune systems and cumulative environmental exposures. AI-enhanced ICU ventilation weaning supports the management of respiratory diseases by continuously analyzing patient-specific data, predicting optimal weaning times, reducing the duration of mechanical ventilation, minimizing complications, and enabling personalized, timely clinical interventions that improve patient outcomes. For example, in June 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that in 2023, chronic obstructive pulmonary disease (COPD) accounted for 3.6% of Australia’s total disease burden and represented 50% of the overall burden from respiratory conditions. Consequently, the rising prevalence of respiratory diseases is fueling the growth of the AI-enhanced ICU ventilation weaning market.

The growing emphasis on personalized medicine is also expected to propel the growth of the AI-enhanced ICU ventilation weaning market. Personalized or precision medicine tailors treatments and healthcare decisions to individual patients based on their genetic makeup, lifestyle, and environmental factors. The focus on personalized medicine is increasing due to advances in genomic technologies and data analytics, which enable more precise and individualized patient care in critical healthcare settings. AI-enhanced ventilation weaning systems support personalized medicine by analyzing patient-specific data to determine the optimal timing for mechanical ventilation removal, improving outcomes through customized treatment protocols. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from 6 in 2022, reflecting an increase of 10 new personalized treatment approvals. Therefore, the growing focus on personalized medicine is driving the growth of the AI-enhanced ICU ventilation weaning market.

In October 2025, Etiometry Inc., a US-based software company specializing in AI-enhanced solutions for ventilator weaning in ICUs, partnered with Hospinorm FZCO to introduce its AI-driven platform to enhance critical care in the UAE. Through this partnership, Hospinorm and Etiometry aim to bring FDA-cleared clinical decision-support technology to the UAE, equipping clinicians with real-time insights, improving patient outcomes, and elevating critical care standards across the region. The platform enables early detection of patient deterioration, standardizes care protocols, and optimizes resource utilization in intensive care units. Hospinorm FZCO is a UAE-based healthcare technology company that provides advanced medical solutions and innovative healthcare technologies.

Major companies operating in the artificial intelligence (AI)-enhanced intensive care unit (icu) ventilation weaning market are Medtronic plc, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Drägerwerk AG & Co. KGaA, Getinge AB, Hamilton Medical AG, Hicuity Health Inc., Etiometry Inc., Clew Medical Ltd., Ambient Clinical Analytics Inc., ResMed Inc., Vyaire Medical, Inc., Mindray Medical International Limited, Zoll Medical Corporation, Baxter International Inc., Siemens Healthineers AG, Smiths Medical (ICU Medical, Inc.), Masimo Corporation, Aeonmed, Timpel S.A.

North America was the largest region in the artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-enhanced intensive care unit (icu) ventilation weaning market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI)-enhanced intensive care unit (icu) ventilation weaning market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the AI-enhanced ICU ventilation weaning market by increasing costs of imported ventilators, sensors, computing hardware, connectivity modules, and advanced analytics systems. Hospitals in North America and Europe are most affected due to reliance on imported critical care equipment, while Asia-Pacific faces higher costs for manufacturing and exporting ventilator components. These tariffs are increasing capital expenditure for ICU upgrades and delaying technology adoption. However, they are also encouraging local assembly of ventilators, regional software development, and investment in domestically produced critical care solutions.

The artificial intelligence (AI)-enhanced intensive care unit (icu) ventilation weaning market research report is one of a series of new reports that provides artificial intelligence (AI)-enhanced intensive care unit (icu) ventilation weaning market statistics, including artificial intelligence (AI)-enhanced intensive care unit (icu) ventilation weaning industry global market size, regional shares, competitors with a artificial intelligence (AI)-enhanced intensive care unit (icu) ventilation weaning market share, detailed artificial intelligence (AI)-enhanced intensive care unit (icu) ventilation weaning market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI)-enhanced intensive care unit (icu) ventilation weaning industry. This artificial intelligence (AI)-enhanced intensive care unit (icu) ventilation weaning market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning refers to the use of AI-driven algorithms to assist in gradually reducing and ultimately discontinuing mechanical ventilation in critically ill patients. It utilizes real-time patient data to predict readiness for weaning, optimize ventilator settings, and minimize complications. This approach aims to improve patient outcomes, shorten ventilation duration, and reduce ICU-related risks.

The main components of AI-enhanced ICU ventilation weaning include software, hardware, and services. Software consists of programs and algorithms that enable computers to analyze data and provide actionable insights. These systems are deployed through on-premises and cloud-based models and are applied in adult, pediatric, and neonatal intensive care units (ICU). End-users include hospitals, specialty clinics, ambulatory surgical centers, and other healthcare providers.

The artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning market consists of revenues earned by entities by providing services such as clinician decision support systems, remote monitoring and tele-ICU services, predictive analytics and risk assessment, workflow optimization solutions, training and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning market also includes sales of ventilator monitoring systems, telerobotic ventilator controllers, and wearable respiratory sensors, and non-invasive ventilation (NIV) devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.